ArticlePediatric surgery international2025
A journey full of surprises: surgical insights from pediatric undifferentiated embryonal liver sarcomas.
Article in Pediatric surgery international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimUndifferentiated embryonal sarcoma of the liver (UESL) presents significant diagnostic and therapeutic challenges due to its rarity and unpredictable clinical course. This study emphasizes the importance of individualized, case-based assessment by highlighting the distinctive preoperative, intraoperative, and postoperative challenges encountered in pediatric UESL patients. MATERIAL AND
methodsWe performed a retrospective review of nine pediatric patients treated for UESL at our institution from 2012 to 2022. We systematically evaluated clinical presentations, radiological assessments, surgical techniques, perioperative findings, treatment protocols, and follow-up outcomes.
resultsEach patient presented unique diagnostic and therapeutic challenges at various management stages. Preoperatively, overlapping radiologic and immunohistochemical features led to diagnostic uncertainty; notably, weak β-catenin positivity and low AFP levels initially resulted in misdiagnosis and incorrect treatment protocol application in one case. Significant intraoperative events included unexpected pulmonary embolism, while another patient developed posterior reversible encephalopathy syndrome (PRES) immediately preoperatively, delaying surgical intervention. Excluding one patient who experienced an unexplained sudden death on postoperative day 5, no other major surgical complications (such as hemorrhage, infection, bile leakage, biliary complications, or sepsis) were recorded. At a median follow-up of 7.2 years (range: 13 months to 12 years), five patients remained disease-free, one patient continued with intermittent chemotherapy, two patients succumbed to progressive metastatic recurrence, and one patient died postoperatively on day 5 due to an unexplained event.
conclusionUESL requires individualized, case-based evaluation and multidisciplinary collaboration. Each patient may present unique diagnostic, surgical, and postoperative management challenges. Awareness of potential complications and the unpredictable nature of UESL highlights the importance of centralized, multidisciplinary care to optimize clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.